Open Access Rheumatology: Research and Reviews Dovepress Optimal Management of Dactylitis in Patients with Psoriatic Arthritis
暂无分享,去创建一个
[1] H. Koenen,et al. Cellular sources of IL‐17 in psoriasis: a paradigm shift? , 2014, Experimental dermatology.
[2] P. Helliwell,et al. Comprehensive Treatment of Dactylitis in Psoriatic Arthritis , 2014, The Journal of Rheumatology.
[3] P. Emery,et al. High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis , 2014, Annals of the rheumatic diseases.
[4] L. Coates,et al. Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. , 2014, Clinical and experimental rheumatology.
[5] L. Misery,et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] D. Gladman,et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.
[7] O. FitzGerald,et al. New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.
[8] A. Armstrong,et al. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis , 2014, Drugs.
[9] A. Gottlieb,et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.
[10] D. Gladman,et al. Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era , 2013, The Journal of Rheumatology.
[11] Toshiyuki Yamamoto. Angiogenic and Inflammatory Properties of Psoriatic Arthritis , 2013, ISRN dermatology.
[12] D. M. van der Heijde,et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial , 2013, Annals of the rheumatic diseases.
[13] Mahboob Rahman,et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. , 2012, Arthritis and rheumatism.
[14] T. Mcclanahan,et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells , 2012, Nature Medicine.
[15] C. Ritchlin,et al. Altered Bone Biology in Psoriatic Arthritis , 2012, Current Rheumatology Reports.
[16] M. Dougados,et al. Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients. , 2012, Clinical and Experimental Rheumatology.
[17] P. Emery,et al. Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails , 2011, Annals of the rheumatic diseases.
[18] Toshiyuki Yamamoto. Psoriatic arthritis: from a dermatological perspective. , 2011, European journal of dermatology : EJD.
[19] A. Gottlieb,et al. Management of psoriatic arthritis from the view of the dermatologist , 2011, Nature Reviews Rheumatology.
[20] A. Barton,et al. Psoriatic arthritis – what the dermatologist needs to know , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.
[21] K. Reich,et al. Nail psoriasis in Germany: epidemiology and burden of disease , 2010, The British journal of dermatology.
[22] P. Gisondi,et al. The Diagnostic and Therapeutic Challenge of Early Psoriatic Arthritis , 2010, Dermatology.
[23] R. Snyder. Psoriatic Arthritis: A Dermatologist’s Perspective , 2010, American journal of clinical dermatology.
[24] M. Benjamin,et al. The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? , 2009, Current opinion in rheumatology.
[25] K. Reich,et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[26] K. Reich,et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque‐type psoriasis , 2009, The British journal of dermatology.
[27] S. Gabriel,et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. , 2009, Arthritis and rheumatism.
[28] M. Benjamin,et al. The Nail as a Musculoskeletal Appendage – Implications for an Improved Understanding of the Link between Psoriasis and Arthritis , 2008, Dermatology.
[29] I. Olivieri,et al. Role of Trauma in Psoriatic Arthritis , 2008, The Journal of Rheumatology.
[30] A. Gottlieb,et al. Treatment recommendations for psoriatic arthritis , 2008, Annals of the rheumatic diseases.
[31] D. Aeschlimann,et al. IL‐23 promotes osteoclast formation by up‐regulation of receptor activator of NF‐κB (RANK) expression in myeloid precursor cells , 2008, European journal of immunology.
[32] D. Boyle,et al. The pathobiology of psoriatic synovium , 2008, Current opinion in rheumatology.
[33] David J J de Gorter,et al. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. , 2008, The Journal of bone and joint surgery. American volume.
[34] N. Kamatani,et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats , 2007, Arthritis research & therapy.
[35] A. Silman,et al. Environmental risk factors for the development of psoriatic arthritis: results from a case–control study , 2007, Annals of the rheumatic diseases.
[36] M. Benjamin,et al. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. , 2007, Arthritis and rheumatism.
[37] D. Sasseville,et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. , 2007, Journal of the American Academy of Dermatology.
[38] I. Olivieri,et al. Dactylitis or "sausage-shaped" digit. , 2007, The Journal of rheumatology.
[39] S. Colucci,et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL‐7 in an in vitro model derived from human psoriatic arthritis , 2007, The Journal of pathology.
[40] Georg Schett,et al. Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.
[41] Dafna Gladman,et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.
[42] B. Dijkmans,et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment , 2006, Annals of the rheumatic diseases.
[43] K. Asadullah,et al. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.
[44] D. Kane,et al. Early psoriatic arthritis. , 2005, Rheumatic diseases clinics of North America.
[45] R. Stern,et al. Epidemiology of psoriatic arthritis in the population of the United States. , 2005, Journal of the American Academy of Dermatology.
[46] D. Gladman,et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.
[47] J. Firth,et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. , 2005, The Journal of rheumatology.
[48] D. Gladman,et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). , 2005, Arthritis and rheumatism.
[49] D. Foell,et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis , 2005, Arthritis research & therapy.
[50] D. Veale,et al. Immunopathology of psoriasis and psoriatic arthritis , 2005, Annals of the rheumatic diseases.
[51] Toshiyuki Yamamoto,et al. Clinical Analysis of 21 Patients with Psoriasis Arthropathy , 2005, The Journal of dermatology.
[52] D. Baeten,et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy , 2005, Arthritis research & therapy.
[53] Di Chen,et al. Bone Morphogenetic Proteins , 2004, Growth factors.
[54] D. Gladman,et al. Dactylitis in psoriatic arthritis: a marker for disease severity? , 2004, Annals of the rheumatic diseases.
[55] F. Luyten,et al. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis , 2004, Annals of the rheumatic diseases.
[56] F. Manguso,et al. Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". , 2003, The Journal of rheumatology.
[57] L Stafford,et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. , 2003, Rheumatology.
[58] E. Schwarz,et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. , 2003, The Journal of clinical investigation.
[59] Alexander Fraser,et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. , 2003, The Journal of rheumatology.
[60] G. Valesini,et al. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis , 2002, Annals of the rheumatic diseases.
[61] L. Laloux,et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis , 2001, Annals of the rheumatic diseases.
[62] R. Winchester,et al. Psoriatic Arthritis Joint Fluids Are Characterized by CD8 and CD4 T Cell Clonal Expansions that Appear Antigen Driven1 2 , 2001, The Journal of Immunology.
[63] D. Reda,et al. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. , 1999, The Journal of rheumatology.
[64] P. Emery,et al. Psoriatic arthritis: a unified concept twenty years on. , 1999, Arthritis and rheumatism.
[65] B. Bresnihan,et al. Predominance of CD8+ T lymphocytes in psoriatic arthritis. , 1999, The Journal of rheumatology.
[66] A. Dunky,et al. T cell derived cytokines in psoriatic arthritis synovial fluids , 1998, Annals of the rheumatic diseases.
[67] B. Leeb,et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. , 1997, The Journal of rheumatology.
[68] T. Ruzicka. Psoriatic arthritis. New types, new treatments. , 1996, Archives of dermatology.
[69] G Evison,et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. , 1994, British journal of rheumatology.
[70] D. Veale,et al. Classification of clinical subsets in psoriatic arthritis. , 1994, British journal of rheumatology.
[71] M. Dougados,et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. , 1991, Arthritis and rheumatism.
[72] P. Tak,et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. , 2012, Arthritis and rheumatism.
[73] M. Genovese,et al. IL-17 receptor and its functional significance in psoriatic arthritis , 2011, Molecular and Cellular Biochemistry.
[74] I. Olivieri,et al. The challenge of early diagnosis of psoriatic arthritis. , 2008, The Journal of rheumatology.
[75] B. Leeb,et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. , 1998, The Journal of rheumatology.
[76] H. Shepard,et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.
[77] W. Eyler,et al. PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.
[78] submit your manuscript | www.dovepress.com , 2022 .